Table 1 Clinical and laboratory data from acute lymphoblastic leukemia patients
From: Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival
Characteristics | Total patients (n = 45) | Cyclin D1 a | p-value | |
|---|---|---|---|---|
Low expression (n = 20) | High expression (n = 20) | |||
Age, years; median (range) | 27 (18–79) | 22 (18–67) | 38 (18–79) | 0.022 |
Gender | ||||
Male, n (%) | 30 (66.7) | 14 (70) | 13 (65) | |
Female, n (%) | 15 (33.3) | 6 (30) | 7 (35) | 0.49 |
Immunophenotype | ||||
B-ALL, n (%) | 35 (79.5) | 14 (70) | 18 (90) | 0.114 |
T-ALL, n (%) | 9 (20.5) | 6 (30) | 2 (10) | |
BCR-ABL1 positive, n (%) | ||||
Positive, n (%) | 10 (22.2) | 1 (5) | 7 (35) | |
Negative, n (%) | 35 (77.8) | 19 (95) | 13 (65) | 0.018 |
Peripheral blood counts, median (range) | ||||
Hemoglobin, g/dL | 9.1 (5.2–15.8) | 7.9 (5.2–15.2) | 9.3 (5.3–15.8) | 0.235 |
WBC, × 109/L | 12.2 (0.8–549.5) | 23.8 (3.2–549.5) | 8.2 (0.8–61.8) | 0.013 |
Platelets, × 109/L | 38 (4–433) | 29 (4–162) | 38 (7–433) | 0.419 |
LDH, median (range); U/L | 1440 (245–13090) | 2625 (270–13090) | 1410 (245–6848) | 0.09 |